A unique cell surface antigen identifying lymphoid malignancies of B cell origin.

L M Nadler; J Ritz; R Hardy; J M Pesando; S F Schlossman; P Stashenko

doi:10.1172/JCI110005

A monoclonal antibody (anti-B1) specific for a unique B cell surface differentiation antigen was used to characterize the malignant cells from patients with leukemias or lymphomas. All tumor cells from patients with lymphomas or chronic lymphocytic leukemias, bearing either monoclonal kappa lambda light chain, expressed the B1 antigen. In contrast, tumor cells from T cell leukemias and lymphomas or acute myeloblastic leukemia were unreactive. Approximately 50% of acute lymphoblastic leukemias (ALL) of non-T origin and 50% of chronic myelocytic leukemia in blast crisis were also anti-B1 reactive. moreover, 21 of 28 patients with the common ALL antigen (CALLA) positive form of ALL were anti-B1 positive, whereas 0 of 13 patients with CALLA negative ALL were reactive. These observations demonstrate that an antigen present on normal B cells is expressed on the vast majority of B cell lymphomas and on approximately 75% of CALLA positive ALL, suggesting that these tumors may share a common B cell lineage.

A unique cell surface antigen identifying lymphoid malignancies of B cell origin.

L M Nadler, J Ritz, R Hardy, J M Pesando, S F Schlossman, and P Stashenko

Article tools

Metrics

Go to

A unique cell surface antigen identifying lymphoid malignancies of B cell origin.

L M Nadler, J Ritz, R Hardy, J M Pesando, S F Schlossman, and P Stashenko

Article tools

Metrics

Go to

Sign up for email alerts